Deanna A. Mele, Ph.D.
Affiliations: | 2009 | Cellular & Molecular Physiology | Sackler School of Graduate Biomedical Sciences (Tufts University) |
Area:
Cell Biology, Molecular BiologyGoogle:
"Deanna Mele"Parents
Sign in to add mentor| Brigitte T. Huber | grad student | 2009 | Sackler School of Graduate Biomedical Sciences (Tufts University) | |
| (DPP2: A novel regulator of cell quiescence and T cell differentiation.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Revenko A, Carnevalli LS, Sinclair C, et al. (2022) Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer. Journal For Immunotherapy of Cancer. 10 |
| Borodovsky A, Barbon CM, Wang Y, et al. (2020) Small molecule AZD4635 inhibitor of AR signaling rescues immune cell function including CD103 dendritic cells enhancing anti-tumor immunity. Journal For Immunotherapy of Cancer. 8 |
| Chandra D, Barbon CM, Borodovsky A, et al. (2020) Abstract A87: The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression in tumor microenvironment and enhances antitumor immunity partly by enhancing CD103+ dendritic cells Cancer Immunology Research. 8 |
| Grimster N, Drew L, Fawell S, et al. (2020) Abstract A56: Releasing the brake on T-cell activation through inhibition of HPK1 Cancer Immunology Research. 8 |
| O' Donovan DH, Mao Y, Mele DA. (2019) The Next Generation of Pattern Recognition Receptor Agonists: Improving Response Rates in Cancer Immunotherapy. Current Medicinal Chemistry |
| Barbon CM, Borodovsky A, Wang Y, et al. (2019) Abstract LB-192: The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression of CD103+ dendritic cells Cancer Research. 79 |
| Langdon S, Hughes A, Taylor MA, et al. (2018) Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity. Oncoimmunology. 7: e1458810 |
| Ghosh S, Taylor A, Chin M, et al. (2016) Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition. The Journal of Biological Chemistry |
| Mele DA, Salmeron A, Ghosh S, et al. (2013) BET bromodomain inhibition suppresses TH17-mediated pathology. The Journal of Experimental Medicine. 210: 2181-90 |
| Mertz JA, Conery AR, Bryant BM, et al. (2011) Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proceedings of the National Academy of Sciences of the United States of America. 108: 16669-74 |